Testicular cancer can spread from the testicle to lymph nodes in the retroperitoneum—the area at the back of the abdomen—and, in some patients, to organs such as the lungs, liver, bones or brain. “Metastatic testicular cancer” means cancer has spread beyond the testicle. “Advanced testicular cancer” often refers to disease with more extensive lymph-node involvement or spread to distant sites.
Even when testicular cancer has spread, it is often treatable and may be curable. The best treatment depends on the exact tumour type, where the cancer has spread, tumour-marker levels, previous treatment and how the cancer responds. Care should be coordinated by a team experienced in germ-cell tumours, including medical oncology, surgical oncology/urologic oncology, radiology and pathology.
A diagnosis of metastatic disease is serious, but it does not automatically mean that treatment cannot work. It is important to obtain an accurate stage and prognosis before deciding on treatment.
A report may use terms such as “bulky retroperitoneal lymphadenopathy”, “multiple pulmonary nodules”, “visceral metastases”, “supraclavicular lymphadenopathy” or “residual metastatic mass”. These phrases need to be interpreted alongside the original testicular histopathology, tumour markers and the full imaging assessment. Not every lung nodule or enlarged lymph node in a patient with cancer is necessarily metastatic.
Treatment planning usually brings together several pieces of information:
The risk group helps guide the chemotherapy regimen and number of cycles. It does not replace individual assessment. In some patients, tumour-marker trends during the first cycle of chemotherapy also provide important information about response.
For many patients with metastatic testicular germ-cell cancer, cisplatin-based combination chemotherapy is the main initial treatment. The regimen and number of cycles depend on whether the tumour is seminoma or NSGCT and on the established prognostic group. Examples used in guideline-based care include BEP (bleomycin, etoposide and cisplatin) and, when bleomycin is unsuitable, EP (etoposide and cisplatin) in selected settings. These medicines require specialist supervision and monitoring.
Treatment may also include surgery to remove residual masses after chemotherapy, particularly for NSGCT, or surgery for selected localised residual or recurrent disease. Radiotherapy has a role in selected seminoma settings. The choice is not made from the scan alone and should be discussed by the treating multidisciplinary team.
Do not stop, delay or change planned cancer treatment based on website information. Ask the treating oncologist to explain the intent, expected benefits, side effects and alternatives for your specific situation.
After chemotherapy for NSGCT, a residual retroperitoneal mass may contain mature teratoma, viable germ-cell cancer, scar tissue or necrosis. In guideline-based pathways, visible residual masses greater than 1 cm are generally evaluated for surgical removal when tumour markers are normal or normalising. The final decision depends on histology, imaging, marker trends, fitness for surgery and previous treatment. Seminoma residual masses are assessed differently; surgery is not routine for every residual seminoma mass.
Cancer can occasionally return after a period of successful treatment, including more than two years after the end of initial treatment. In late-relapsing NSGCT, surgery to remove resectable disease may be particularly important, sometimes with chemotherapy depending on the findings. These cases should be reviewed at a centre experienced in recurrent germ-cell tumours.
Some patients with marker-negative, limited retroperitoneal lymph-node disease may be candidates for primary RPLND after careful staging and specialist review. This is not appropriate for every patient. Elevated or rising tumour markers, widespread disease, tumour type and the size or location of the nodes may favour systemic treatment instead.
Occasionally, residual lesions remain in the chest or other sites after chemotherapy. Whether these need surgery, further systemic treatment or observation depends on the tumour type, marker levels, response, resectability and multidisciplinary assessment.
Retroperitoneal masses can lie close to the aorta, inferior vena cava, renal vessels, ureters, bowel and other structures. After chemotherapy or previous surgery, scar tissue may make dissection more difficult. The operation may require removal of lymph-node tissue and, in selected cases, repair or removal of adjacent structures involved by the mass.
The surgical plan should be based on review of the actual CT images, not only the written report. Depending on the case, input from medical oncology, radiology, pathology, vascular surgery, anaesthesia and other specialists may be needed. The surgical approach—open, laparoscopic or robotic—is selected according to disease extent, prior treatment, the need for complete removal and the team’s expertise. A minimally invasive approach is not suitable for every complex mass.
AFP, beta-hCG and LDH help monitor testicular germ-cell cancer, but each marker has limitations. A rising AFP or beta-hCG after orchidectomy or during follow-up may indicate persistent or recurrent disease and needs prompt assessment. Borderline or unexpected results sometimes require repeat testing and review of possible non-cancer causes before major decisions are made.
If markers rise or fail to decline as expected during treatment, the oncology team may reassess the diagnosis, staging, treatment response and prognosis. Surgery alone is generally not the first treatment for widespread marker-positive disease. Decisions about salvage chemotherapy, high-dose chemotherapy with stem-cell support, surgery or clinical trials are made by specialists based on the complete clinical picture.
Late relapse means testicular cancer returns more than two years after successful completion of initial treatment. It is uncommon, but it can occur even after a long period without symptoms. A new retroperitoneal mass, rising tumour markers, persistent abdominal or back pain, or a new abnormal scan should be assessed in the context of the previous cancer history.
Late relapse of NSGCT may contain teratoma or other tumour components and may require surgery when complete removal is feasible. The treatment strategy differs by histology and previous treatment, so expert review of the original and new pathology can be important.
These symptoms can have causes other than cancer. If a patient with known testicular cancer develops new or worsening symptoms, they should contact their treating team promptly. Severe breathlessness, new neurological symptoms or other acute severe symptoms require urgent medical assessment.
Chemotherapy and surgery can have short- and long-term effects. Depending on the treatment, these may include fatigue, nausea, infection risk, kidney or hearing effects, nerve symptoms, lung toxicity with some regimens, changes in fertility, hormonal effects and sexual-health concerns. Not every patient experiences all these effects, and risk varies by regimen, dose and individual health.
Discuss sperm banking before treatment whenever feasible, and do not delay urgent treatment without advice from the oncology team. Follow-up may include tumour markers, imaging, examination and monitoring for late effects. Ask about exercise, return to work, fertility, testosterone symptoms, sexual function, psychological support and cardiovascular or other long-term health considerations where relevant.
Many patients with metastatic testicular germ-cell cancer can be treated successfully, and cure remains possible even when disease has spread. The outlook depends on the tumour type, risk group, metastatic sites and response to treatment.
Cisplatin-based chemotherapy is the main treatment for many patients with metastatic disease. Selected cases may also need surgery or radiotherapy. The correct plan depends on histology, markers, stage and risk group.
Surgery can be important for selected residual or recurrent masses, but it is not a substitute for chemotherapy when systemic treatment is indicated.
It means enlarged lymph nodes or a nodal mass in the back of the abdomen. In a patient with testicular cancer, the finding needs interpretation with tumour markers, histology and the full scan.
Yes, late relapse is uncommon but possible. New symptoms, rising markers or an abnormal scan should be reviewed promptly, even after several years.
Only selected cases. The approach depends on the mass, prior chemotherapy or surgery, involvement of major vessels and the need for complete removal.
For complex, recurrent or post-chemotherapy disease, review by a team experienced in testicular germ-cell tumours can help confirm staging, treatment options and the surgical plan.
Normal markers do not rule out teratoma or all residual disease. The scan, original histology, response to treatment and clinical context determine the next step.
| Group | AFP (ng/mL) | hCG (IU/L) | LDH |
|---|---|---|---|
| Good | below 1,000 | below 5,000 | below 1.5 × upper limit of normal |
| Intermediate | 1,000 to 10,000 | 5,000 to 50,000 | 1.5 to 10 × upper limit of normal |
| Poor | above 10,000 | above 50,000 | above 10 × upper limit of normal |
Many patients with metastatic germ-cell tumours are treated with curative intent. Cisplatin-based chemotherapy, usually BEP, is the backbone, and surgery for a residual mass may follow. Outcome depends on the IGCCCG risk group, so staging and markers are reviewed first.
The IGCCCG classification groups metastatic germ-cell tumours as good, intermediate or poor risk using the primary site, sites of metastasis and pre-chemotherapy AFP, beta-hCG and LDH. It guides the choice and intensity of chemotherapy.
Surgery, usually post-chemotherapy RPLND, is considered when a residual retroperitoneal mass larger than 1 cm remains in a non-seminomatous tumour after AFP and beta-hCG have normalised.
Selected videos and anonymised case summaries from Dr Swati Shah’s testicular cancer practice, shared for patient education. Every patient’s plan is individual, and a past case does not predict an individual result.
Advanced testicular cancer can still be curable, even when large residual lymph node masses remain after chemotherapy.
In this case, a 30-year-old man with a mixed germ cell tumor of the testis received systemic chemotherapy and subsequently underwent evaluation for a residual retroperitoneal lymph node mass. PET-CT showed significant residual masses measuring approximately 6 × 5 cm and 5 × 5 cm, located close to major blood vessels, including the aorta, inferior vena cava (IVC), and renal vessels.
Because of the size and location of the residual disease, surgery was technically challenging. The patient underwent exploratory laparotomy with retroperitoneal lymph node dissection (RPLND). Despite the close relationship of the tumor to the major vessels, a complete surgical resection was achieved safely, with removal of all visible residual tumor tissue.
When a testicular tumour is suspected, the surgical approach is extremely important. A scrotal incision should generally be avoided because it can disrupt the normal lymphatic drainage pathways of the testis and potentially increase the risk of local tumour contamination and altered patterns of spread.
The standard oncological procedure for a suspected testicular malignancy is high inguinal orchidectomy. Through an inguinal approach, the testis is delivered and removed along with the spermatic cord and its vascular and lymphatic pedicle, providing appropriate oncological control and allowing accurate histopathological diagnosis.
This is an important surgical principle: the first incision matters. An incorrect approach can complicate subsequent management, while the appropriate initial procedure can help ensure proper staging and treatment.
जब टेस्टिकुलर ट्यूमर (Testicular Tumour) का संदेह हो, तो सर्जरी का सही तरीका बहुत महत्वपूर्ण होता है। आमतौर पर अंडकोष (Scrotum) पर चीरा लगाने से बचना चाहिए, क्योंकि इससे अंडकोष की सामान्य लिम्फेटिक ड्रेनेज (Lymphatic drainage) प्रभावित हो सकती है और स्थानीय रूप से ट्यूमर कोशिकाओं के फैलने तथा बीमारी के फैलाव के तरीके में बदलाव का जोखिम बढ़ सकता है।
संदिग्ध टेस्टिकुलर कैंसर में मानक ऑन्कोलॉजिकल सर्जरी हाई इंग्वाइनल ऑर्किडेक्टॉमी (High Inguinal Orchidectomy) है। इसमें जांघ के ऊपरी हिस्से के पास इंग्वाइनल (Inguinal) रास्ते से अंडकोष को बाहर निकालकर, उसे स्पर्मेटिक कॉर्ड (Spermatic cord) तथा उसकी रक्त वाहिकाओं और लिम्फेटिक पेडिकल (Lymphatic pedicle) सहित हटाया जाता है। इससे उचित कैंसर सर्जरी सुनिश्चित होती है और सही हिस्टोपैथोलॉजिकल डायग्नोसिस (Histopathological diagnosis) में मदद मिलती है।
यह एक महत्वपूर्ण सर्जिकल सिद्धांत है: पहला चीरा बहुत मायने रखता है। गलत तरीके से किया गया पहला ऑपरेशन आगे के उपचार को जटिल बना सकता है, जबकि सही शुरुआती सर्जिकल प्रक्रिया बीमारी की उचित स्टेजिंग और आगे के उपचार में मदद करती है।
This video presents a compelling testimonial from a testicular cancer survivor who received life-saving treatment from Dr. Swati Shah, an expert Uro and Gynecological Oncologist. In the brief clip, the patient recounts their challenging medical journey, focusing on the critical decision-making process regarding their surgical treatment plan. Initially confronted with the difficult prospect of traditional open surgery—which typically involves a longer, more painful healing process—the patient instead opted for a state-of-the-art robotic surgery performed by Dr. Shah. The survivor shares how this advanced, minimally invasive approach made a massive difference in their overall recovery.
In the video, He speaks in Gujarati, sharing his personal experience. He explains that he initially visited the clinic because he was experiencing significant pain. After a thorough medical evaluation, he was diagnosed with cancer and advised to undergo surgical intervention. Guided by the medical expertise of Dr. Swati Shah, He confidently went ahead with the recommended operation. The surgery was a success, and he reports receiving a highly positive response to the procedure. Following the operation, his comprehensive treatment plan also included a round of chemotherapy to reduce the risk of relapse.
The patient explains that he was initially diagnosed with testicular cancer five years ago. Unfortunately, eight months prior to the video, he faced a recurrence involving a retroperitoneal lymph node. After finding Dr. Swati Shah online, he underwent a complex robotic Retroperitoneal Lymph Node Dissection (RPLND) surgery performed by her. Speaking just two months post-operation, the patient highlights his remarkably smooth and rapid recovery, noting that his follow-up medical reports have all been positive. He expresses deep gratitude and recommends Dr. Shah.
“Dr. Swati Shah operated successfully and provided excellent care throughout the treatment. She is highly skilled, compassionate, and undoubtedly the best doctor for testis cancer in Ahmedabad. We are very thankful for her guidance and expertise”
Raval Prakash · Patient, Google review
“From the first meeting, Dr. Swati Shah explained every detail of the diagnosis and surgical procedure with great clarity. During the surgery, her precision and care were remarkable, and post-surgery recovery was smooth under her guidance.”
Dhyey Patel · Patient, Google review
“I had an excellent experience with Dr. Swati Shah. She is one of the most skilled and compassionate doctors I have ever met. Her approach is very professional, and she explains every step of the treatment with great patience and clarity. The surgery was successful, and recovery was smooth under her guidance.”
raju panchal · Patient, Google review
A 32-year-old man had recurrence of NSGCT after orchidectomy and chemotherapy, with a significant residual retroperitoneal mass. Surgery was planned to address chemo-resistant teratoma and prevent local progression.
A 28-year-old man had a significant residual retroperitoneal mass after systemic chemotherapy for an NSGCT. Because of its relation to major vessels, complete resection was the surgical aim, to reduce the risk of malignant transformation or relapse.
Details are anonymised and shown for education only.
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with experience in cancer surgery, robotic surgery and complex retroperitoneal tumour surgery. Her work includes testicular cancer surgery, RPLND and selected complex retroperitoneal masses. Treatment decisions for advanced or recurrent testicular cancer are individualised and should be made in coordination with a team experienced in germ-cell tumours.
For an opinion about advanced, recurrent or metastatic testicular cancer, bring the original pathology, tumour-marker trends, chemotherapy records and actual imaging. A review can help clarify the stage, treatment response, whether surgery has a role, and how to plan care with the treating oncology team.
Shah’s Cancer & Robotic Surgery Centre, Gota, Ahmedabad | Apollo Hospital International, Ahmedabad
Appointment contact: +91 63590 11009
This page provides general educational information and does not replace an individual medical consultation. Do not delay urgent assessment or prescribed treatment while seeking online information.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
